Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You must have gotten in at much lower levels. Congratulations! But from these levels, the way this stock trades, nobody is going to make any money.
Why does SNST refuse to release audited financials? Other Pink Sheet companies do it, why not SNST?
No SEC page for SNST. No audited financials for SNST. Tiny daily volume and HUGE untradable spreads. Someone tell me the bullish case here... I don't see it.
Wow, some days volume is nearly zero! How do people trade this?
Seems SNST just bounces from $$1.50 to $2.50 with no real direction and with untradable, horrific spreads. Volume some days in nearly non-existent. Difficult to see how anyone would choose to buy and hold this thing.
"Beach"? Somebody call me???
It's been tough watching the price slide, and certainly not what I expected. But I think it's back up from here.
Gene's been pretty quiet lately. Guessing he's ready to unleash some positive PRs related to brewing the nano materials in the new larger tanks.
Guessing we'll base at $1.20 and head higher from there.
NNVC has plenty of money in the bank, so the lower share price won't affect progress toward Phase I trials.
NNVC is listed on an NYSE affiliated exchange. It's the old AMEX exchange, which was merged with the NYSE years ago to become the "NYSE Market" exchange.
Why on earth is this such a difficult concept to grasp?
RIDICULOUS! This is not "trash", and there are no "embarrassing failures".
This is a real company with real science that's been making steady progress throughout their nine year history from a Pink sheet company all the way to an NYSE affiliated exchange. They have no debt, $40M in the bank, and are about to begin TOX studies on the way to human clinical trials next year.
The science is real.
The science is real.
No, not "the past", rather the foundation of the future.
NNVC FluCide's EXCELLENT Pre-Clinical Results Recap!
Lest we forget in the face of all the opposing points of view, here are snippets from a recent PR which detailed a presentation by company president Diwan to an Influenza Conference earlier in the month. His presentation recapped the EXCELLENT animal trial results from previous studies which form the basis for the push toward human trials for FluCide. THIS is the science. In my opinion THIS is why this company will succeed and why share price will eventually explode.
http://finance.yahoo.com/news/nanoviricides-president-dr-diwan-presented-120000451.html
ALL of the FluCide treated animals survived, while NONE of the non-treated animals survived:
Dr. Diwan discussed the nanoviricides® technology platform, and presented the pre-clinical data on the Company’s first drug candidate, NV-INF-1, Injectable FluCide™, to treat all influenza infections in hospitalized patients. Influenza A H1N1 infected animals treated with FluCide survived the full 21-day observation period, whereas animals treated with 40mg/kg/d oseltamivir phosphate (Tamiflu®) survived only 8 days in this highly lethal study. Influenza A/WS/33/ (H1N1) virus was used in this study. The highly lethal infectious dose of 1M viral particles at time 0 h followed by another 1M virus particles at 23h that was employed caused uniform lethality in 5 days in untreated mice. Body weight began to decline in the infected, untreated mice, by days 2-3 days and continued to decline until death. The Oseltamivir-treated mice maintained body weight only through day 5, which declined thereafter until death. Similar to the survival results, the mice treated with NV-INF-1 maintained their body weight substantially longer, through day 14. NV-INF-1 demonstrated an unparalleled 1,000-fold reduction in lung viral load compared to untreated animals on day 4 in this lethal animal model study.
The pre-clinical safety profile for FluCide is extraordinary, essentially perfect:
Dr. Diwan also discussed the extremely high safety of NV-INF-1 observed in preliminary safety/toxicology studies. He noted that no significant changes in all observed parameters were found even at the maximum feasible dose of approximately 2,700 mg/kg/d repeatedly given for five consecutive days.
The potential market for the company's combined portfolio of drugs once through FDA approval in the coming years is HUGE:
The total market size addressed by the Company’s current drug programs is estimated at about $50 billion. In addition to Injectable FluCide, the Company is working on five more commercially important drug candidates, namely: DengueCide™, HerpeCide™, HIVCide™, Oral FluCide™ for out-patients, and a broad-spectrum antiviral drug for viral diseases of the external eye. All of our programs are for therapeutics to treat viral infections. Our drugs are expected to be useful as prophylactics as well. DengueCide has recently received orphan drug designation by the US FDA as well as the European EMA.
-----
The company market cap is currently around $220M. If all drugs succeed through approval in the coming years (not guaranteed), picking a conservative multiplier of five times annual sales, on the high end the company could potentially be valued as high as $250B, for a one thousand times share price appreciation. In that best case scenario, share price under the current post-split structure could be north of $4,000 per share. Or under far more conservative assumptions, maybe share price appreciates only one forth that magnitude, to "only" $1,000 a share? Even reduce that by another factor of four... maybe "only" $250 a share?
Best to all
The rallies have been on BIG volume, the declines and flat trading on small volume. This is EXATLY the desired pattern.
Thanks for noticing!
Speaking of the ACTUAL SCIENCE: Recap of NNVC FluCide's EXCELLENT Pre-Clinical Results!
Lest we forget in the swill of all the opposing points of view, here are snippets from a recent PR which detailed a presentation by company president Diwan to an Influenza Conference earlier in the month. His presentation recapped the EXCELLENT animal trial results from previous studies which form the basis for the push toward human trials for FluCide. THIS is the science. In my opinion THIS is why this company will succeed and why share price will eventually explode.
http://finance.yahoo.com/news/nanoviricides-president-dr-diwan-presented-120000451.html
ALL of the FluCide treated animals survived, while NONE of the non-treated animals survived:
Dr. Diwan discussed the nanoviricides® technology platform, and presented the pre-clinical data on the Company’s first drug candidate, NV-INF-1, Injectable FluCide™, to treat all influenza infections in hospitalized patients. Influenza A H1N1 infected animals treated with FluCide survived the full 21-day observation period, whereas animals treated with 40mg/kg/d oseltamivir phosphate (Tamiflu®) survived only 8 days in this highly lethal study. Influenza A/WS/33/ (H1N1) virus was used in this study. The highly lethal infectious dose of 1M viral particles at time 0 h followed by another 1M virus particles at 23h that was employed caused uniform lethality in 5 days in untreated mice. Body weight began to decline in the infected, untreated mice, by days 2-3 days and continued to decline until death. The Oseltamivir-treated mice maintained body weight only through day 5, which declined thereafter until death. Similar to the survival results, the mice treated with NV-INF-1 maintained their body weight substantially longer, through day 14. NV-INF-1 demonstrated an unparalleled 1,000-fold reduction in lung viral load compared to untreated animals on day 4 in this lethal animal model study.
The pre-clinical safety profile for FluCide is extraordinary, essentially perfect:
Dr. Diwan also discussed the extremely high safety of NV-INF-1 observed in preliminary safety/toxicology studies. He noted that no significant changes in all observed parameters were found even at the maximum feasible dose of approximately 2,700 mg/kg/d repeatedly given for five consecutive days.
The potential market for the company's combined portfolio of drugs once through FDA approval in the coming years is HUGE:
The total market size addressed by the Company’s current drug programs is estimated at about $50 billion. In addition to Injectable FluCide, the Company is working on five more commercially important drug candidates, namely: DengueCide™, HerpeCide™, HIVCide™, Oral FluCide™ for out-patients, and a broad-spectrum antiviral drug for viral diseases of the external eye. All of our programs are for therapeutics to treat viral infections. Our drugs are expected to be useful as prophylactics as well. DengueCide has recently received orphan drug designation by the US FDA as well as the European EMA.
-----
The company market cap is currently around $220M. If all drugs succeed through approval in the coming years (not guaranteed), picking a conservative multiplier of five times annual sales, on the high end the company could potentially be valued as high as $250B, for a one thousand times share price appreciation. In that best case scenario, share price under the current post-split structure could be north of $4,000 per share. Or under far more conservative assumptions, maybe share price appreciates only one forth that magnitude, to "only" $1,000 a share? Even reduce that by another factor of four... maybe "only" $250 a share?
NONSENSE! The way in which NanoViricides has farmed out their pre-clinical research has been masterful! It has somewhat increased the time required to conduct some of the studies, but it's TREMENDOUSLY REDUCED THE COST of those studies for the company and the shareholders!
This once Pink Sheet company has in nine years progressed through the BB all the way to become an NYSE affiliated company, NOW WITH NO DEBT, $40M IN THE BANK, AND ABOUT TO BEGIN THEIR TOX STUDY LEADING TO HUMAN CLINICAL TRIALS AND DRUG APPROVAL!
Had NNVC been required to themselves PAY for all the pre-clinical testing, the costs would have very significantly diluted shareholder value.
Their strategy has been MASTERFUL! How many companies make it from the Pink Sheets all the way to an NYSE affiliated exchange? Virtually none. Virtually none.
48 Institutions Believe in the SCIENCE: Hold $11M+ Stock!!!
These include: VANGUARD GROUP INC, GOLDMAN SACHS GROUP INC, GEODE CAPITAL MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP LLP, UBS AG, COLONY GROUP LLC, KCG HOLDINGS INC, AQR CAPITAL MANAGEMENT LLC, JANE STREET GROUP LLC, NORTHERN TRUST CORP, STALEY CAPITAL ADVISERS INC, and SCHWAB CHARLES INVESTMENT MANAGEMENT INC.
While a few may be Russell Index Funds with limited discretion, the balance of these institutional investors apparently believe the science, and believe the risk reward ratio of an investment in NanoViricides argues for ownership!
http://www.nasdaq.com/symbol/nnvc/institutional-holdings
best to all!
Contrived, baseless ad hominem attacks against NanoViricides' officers do nothing to further an understanding of this company, or of the actual science underlying its nanotechnological approach to the cure of viral disease.
Simply not true.
Delays in starting the TOX have no bearing on the length of time required for its completion once it has started.
TOX will start soon, and once begun, will take a few months to complete, and a few more months to write up and submit. I'll take BK's estimates that he's provided more than once today.
Constantly rehashing the delays we've all experienced getting to this point won't be the least bit relevant once the TOX studies have begun.
Well that's a step up! At least now you're predicting the successful completion of the TOX studies, although in a time frame about three times what will likely be the case.
Thanks for your support!
About length of TOX once started? Yes, and thanks for your validation.
Beginning to completion of analysis, 6 months about right!
Thanks for your agreement on this important matter!
SIMPLY NOT TRUE!!! TOX won't take more than a few months to run, and perhaps another month or two or three to evaluate and write up.
Talk of the TOX studies taking a full year is nonsense, made up, and false.
I think we're witnessing the birth of the new fictitious Meme regarding NNVC -- a grossly exaggerated length of time to complete the TOX studies. Notice the "old" Meme was that TOX wouldn't even START this year...
Of course it will. TOX starts soon, probably in weeks.
No, not true. We've been over the "peer reviewed" argument dozens of times. It's not appropriate for developmental stage companies to publish their results in journals.
Fantastic pre-clinical research success is not a "claim", it's proven science.
It's proven science that the NanoViricides work wonderfully well in the 5,000 animals in which they have been administered. And these pre-clinical trials were conducted by multiple independent labs and universities and government facilities. It's not just a "claim".
TOX studies will begin soon, and then on to Human Clinical Trials next year.
Yes it will. And by next summer we'll be into Human Clinical Trials. And share price will be multiples above current levels.
And obviously, what you label so boldly as "fact" is merely your opinion...
Agreed! NNVC made the Wall Street Journal today!!!
Referenced in today's PR -- NNVC FluCide's EXCELLENT Pre-Clinical Results Recap!
Lest we forget in the swill of all the opposing points of view, here are snippets from a recent PR which detailed a presentation by company president Diwan to an Influenza Conference earlier in the month. His presentation recapped the EXCELLENT animal trial results from previous studies which form the basis for the push toward human trials for FluCide. THIS is the science. In my opinion THIS is why this company will succeed and why share price will eventually explode.
http://finance.yahoo.com/news/nanoviricides-president-dr-diwan-presented-120000451.html
ALL of the FluCide treated animals survived, while NONE of the non-treated animals survived:
Dr. Diwan discussed the nanoviricides® technology platform, and presented the pre-clinical data on the Company’s first drug candidate, NV-INF-1, Injectable FluCide™, to treat all influenza infections in hospitalized patients. Influenza A H1N1 infected animals treated with FluCide survived the full 21-day observation period, whereas animals treated with 40mg/kg/d oseltamivir phosphate (Tamiflu®) survived only 8 days in this highly lethal study. Influenza A/WS/33/ (H1N1) virus was used in this study. The highly lethal infectious dose of 1M viral particles at time 0 h followed by another 1M virus particles at 23h that was employed caused uniform lethality in 5 days in untreated mice. Body weight began to decline in the infected, untreated mice, by days 2-3 days and continued to decline until death. The Oseltamivir-treated mice maintained body weight only through day 5, which declined thereafter until death. Similar to the survival results, the mice treated with NV-INF-1 maintained their body weight substantially longer, through day 14. NV-INF-1 demonstrated an unparalleled 1,000-fold reduction in lung viral load compared to untreated animals on day 4 in this lethal animal model study.
The pre-clinical safety profile for FluCide is extraordinary, essentially perfect:
Dr. Diwan also discussed the extremely high safety of NV-INF-1 observed in preliminary safety/toxicology studies. He noted that no significant changes in all observed parameters were found even at the maximum feasible dose of approximately 2,700 mg/kg/d repeatedly given for five consecutive days.
The potential market for the company's combined portfolio of drugs once through FDA approval in the coming years is HUGE:
The total market size addressed by the Company’s current drug programs is estimated at about $50 billion. In addition to Injectable FluCide, the Company is working on five more commercially important drug candidates, namely: DengueCide™, HerpeCide™, HIVCide™, Oral FluCide™ for out-patients, and a broad-spectrum antiviral drug for viral diseases of the external eye. All of our programs are for therapeutics to treat viral infections. Our drugs are expected to be useful as prophylactics as well. DengueCide has recently received orphan drug designation by the US FDA as well as the European EMA.
-----
The company market cap is currently around $220M. If all drugs succeed through approval in the coming years (not guaranteed), picking a conservative multiplier of five times annual sales, on the high end the company could potentially be valued as high as $250B, for a one thousand times share price appreciation. In that best case scenario, share price under the current post-split structure could be north of $4,000 per share. Or under far more conservative assumptions, maybe share price appreciates only one forth that magnitude, to "only" $1,000 a share? Even reduce that by another factor of four... maybe "only" $250 a share?
Best to all.
Before it starts: About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
http://finance.yahoo.com/news/seethruequity-issues-note-nanoviricides-highlighting-123000152.html
No they wouldn't, that's ridiculous.
NNVC has 48 Institutional investors for God's sake.
Well I actually AM a shareholder, and I don't agree with any of your opinions or positions!
I see them as having done something amazing in taking the company from a Pink Sheet shell 9 years ago, through the Bulletin Board, and now to an NYSE listed exchange, all with little or no debt AND 40 MILLION DOLLARS IN THE BANK, enough to get them well into Clinical trials!
We're very close to the start of the TOX studies, which will be the gateway to human Clinical trials and then approval of the first drug, FluCide.
So yes... your statements are ridiculous. And I say that with the authority of someone who actually has a pretty good deal of money invested here.
Ridiculous nonsense by the boat load...
You're conflating what a shareholder said (me) with what the CEO said, and then implying that because the numbers aren't exactly the same the CEO somehow is not being truthful?
It's BILLIONS of dollars either way! What's the difference?
When this company has a drug on the market that's annually worth ANY number of billion dollars, then share price will be 100 times current levels.
And thanks for pointing out it might only be FIVE BILLION ANNUALLY!!!
Fine $25B! Thanks for the update!!!
There WAS no money in Ebola when he made that statement. There also was no epidemic with the potential to be a calamitous worldwide disaster. It was not in the headlines.
But now, there IS a hideous world wide epidemic potential, and there IS grant money available .
The fact that NNVC decided back then to pursue FluCide as their first approved drug was wise, as the potential market for the first ever treatment for viral Flu is in the $5B a year range -- FIVE BILLION PER YEAR. And back then the financial potential for a successful Ebola drug was next to nothing. As fincncial stewards of the company, it would have made no sense to pursue EbolaCide back then over FluCide. Advancing FluCide was the appropriate choice.
To take his statement from years ago out of context and imply it somehow shows the company is only in it for the money is beyond ridiculous. They did the rational, appropriate thing, that everyone who does the least amount of DD understands.